167 related articles for article (PubMed ID: 30767401)
21. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
[TBL] [Abstract][Full Text] [Related]
22. High levels of Nrf2 determine chemoresistance in type II endometrial cancer.
Jiang T; Chen N; Zhao F; Wang XJ; Kong B; Zheng W; Zhang DD
Cancer Res; 2010 Jul; 70(13):5486-96. PubMed ID: 20530669
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA‑34b expression enhances chemosensitivity of endometrial cancer cells to paclitaxel.
Yanokura M; Banno K; Aoki D
Int J Oncol; 2020 Nov; 57(5):1145-1156. PubMed ID: 33300049
[TBL] [Abstract][Full Text] [Related]
24. An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines.
Smith JA; Brown J; Martin MC; Ramondetta LM; Wolf JK
Gynecol Oncol; 2004 Jan; 92(1):314-9. PubMed ID: 14751176
[TBL] [Abstract][Full Text] [Related]
25. The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin.
Chon HS; Marchion DC; Xiong Y; Chen N; Bicaku E; Stickles XB; Bou Zgheib N; Judson PL; Hakam A; Gonzalez-Bosquet J; Wenham RM; Apte SM; Lancaster JM
Gynecol Oncol; 2012 Jan; 124(1):119-24. PubMed ID: 22032837
[TBL] [Abstract][Full Text] [Related]
26. Sensitivity of endometrial cancer cells from primary human tumor samples to new potential anticancer peptide lactaptin.
Koval OA; Sakaeva GR; Fomin AS; Nushtaeva AA; Semenov DV; Kuligina EV; Gulyaeva LF; Gerasimov AV; Richter VA
J Cancer Res Ther; 2015; 11(2):345-51. PubMed ID: 26148598
[TBL] [Abstract][Full Text] [Related]
27. Cisplatin increases B-cell-lymphoma-2 expression via activation of protein kinase C and Akt2 in endometrial cancer cells.
Rouette A; Parent S; Girouard J; Leblanc V; Asselin E
Int J Cancer; 2012 Apr; 130(8):1755-67. PubMed ID: 21618512
[TBL] [Abstract][Full Text] [Related]
28. [Study of mechanism of medroxyprogesterone 17-acetate on the cancer stem cell-like properties of human endometrial cancer].
Liu BJ; Li XP; Zhao LJ; Wang JL; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2013 Oct; 48(10):772-7. PubMed ID: 24406136
[TBL] [Abstract][Full Text] [Related]
29. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY
Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408
[TBL] [Abstract][Full Text] [Related]
30. Loss of AF-6/afadin induces cell invasion, suppresses the formation of glandular structures and might be a predictive marker of resistance to chemotherapy in endometrial cancer.
Yamamoto T; Mori T; Sawada M; Matsushima H; Ito F; Akiyama M; Kitawaki J
BMC Cancer; 2015 Apr; 15():275. PubMed ID: 25879875
[TBL] [Abstract][Full Text] [Related]
31. Acquired AKT-inhibitor Resistance Is Mediated by ATP-binding Cassette Transporters in Endometrial Carcinoma.
Takagi S; Onishi T; Takashima T; Shibahara K; Mori M
Anticancer Res; 2023 Jun; 43(6):2501-2507. PubMed ID: 37247888
[TBL] [Abstract][Full Text] [Related]
32. Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study.
Nagao S; Nishio S; Michimae H; Tanabe H; Okada S; Otsuki T; Tanioka M; Fujiwara K; Suzuki M; Kigawa J
Gynecol Oncol; 2013 Dec; 131(3):567-73. PubMed ID: 24076450
[TBL] [Abstract][Full Text] [Related]
33. Long non-coding RNA tumor suppressor candidate 7 advances chemotherapy sensitivity of endometrial carcinoma through targeted silencing of miR-23b.
Shang C; Lang B; Ao CN; Meng L
Tumour Biol; 2017 Jun; 39(6):1010428317707883. PubMed ID: 28653877
[TBL] [Abstract][Full Text] [Related]
34. Overcoming paclitaxel resistance in uterine endometrial cancer using a COX-2 inhibitor.
Hasegawa K; Ishikawa K; Kawai S; Torii Y; Kawamura K; Kato R; Tsukada K; Udagawa Y
Oncol Rep; 2013 Dec; 30(6):2937-44. PubMed ID: 24100466
[TBL] [Abstract][Full Text] [Related]
35. Potential use of the adenosine triphosphate cell viability assay in endometrial cancer.
Tam KF; Ng TY; Tsang PC; Li CF; Ngan HY
J Soc Gynecol Investig; 2006 Oct; 13(7):518-22. PubMed ID: 16979354
[TBL] [Abstract][Full Text] [Related]
36. Targeting RNF8 effectively reverses cisplatin and doxorubicin resistance in endometrial cancer.
Yang B; Ke W; Wan Y; Li T
Biochem Biophys Res Commun; 2021 Mar; 545():89-97. PubMed ID: 33548629
[TBL] [Abstract][Full Text] [Related]
37. What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study.
Nagao S; Nishio S; Okada S; Otsuki T; Fujiwara K; Tanabe H; Takano M; Hasumi Y; Takei Y; Hasegawa T; Matsumoto T; Fujiwara K; Takekuma M; Nakamura K; Shimada M; Suzuki M; Kigawa J
Cancer Chemother Pharmacol; 2015 Aug; 76(2):335-42. PubMed ID: 26092322
[TBL] [Abstract][Full Text] [Related]
38. Palmitate Enhances the Efficacy of Cisplatin and Doxorubicin against Human Endometrial Carcinoma Cells.
Wu ZS; Huang SM; Wang YC
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008502
[TBL] [Abstract][Full Text] [Related]
39. Imatinib sensitizes endometrial cancer cells to cisplatin by targeting CD117-positive growth-competent cells.
Zhang X; Kyo S; Nakamura M; Mizumoto Y; Maida Y; Bono Y; Takakura M; Fujiwara H
Cancer Lett; 2014 Apr; 345(1):106-14. PubMed ID: 24333732
[TBL] [Abstract][Full Text] [Related]
40. Cyclin A2 confers cisplatin resistance to endometrial carcinoma cells via up-regulation of an Akt-binding protein, periplakin.
Suzuki A; Horiuchi A; Ashida T; Miyamoto T; Kashima H; Nikaido T; Konishi I; Shiozawa T
J Cell Mol Med; 2010 Sep; 14(9):2305-17. PubMed ID: 19583808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
